Pharmaceuticals & Biotech U.K. Community

Innovative niches in the market designed to tackle large problems. This company will be one to watch in the UK.Read more

Active Pipeline: HG-CT-1 - Hemogenyx CAR-T for R/R AML + expanding to pediatrics in H1 2025 targeting FLT3 which has recently been proven as an extremely promising and effective target. Significant interest in CAR-T treatments with each treatment 200k+, licensing deals in the range of 500m->1bn+ (including milestone payments) CDX - Building on same FLT3 target expands use of bi-specific antibody to a whole range of blood borne cancers and diseases including auto-immune.Read more

March Madness is here, or so they say on the basketball courts. But Marchs madness is slowly moving off to more than just the courts.Read more

Key Takeaways Robust growth in vaccines and specialty medicines, alongside innovation in oncology and immunology, positions GSK for sustained revenue and margin expansion. Diversification, operational efficiencies, and accelerated R&D enhance resilience, supporting strong long-term sales and earnings potential despite industry pressures.Read more

PureTech Health’s business can look strong one year and weak the next because much of its money depends on partner milestones and drug sales royalties that don’t arrive on a steady schedule. The upside is that its “hub-and-spoke” pipeline could still pay off over time, but delays in outside funding, trial progress, or early sales performance could quickly change the picture.Read more

Shield Therapeutics bets heavily on one key iron-deficiency medicine, and growing competition plus tighter rules on drug pricing could make its path ahead bumpier than many expect. At the same time, rising prescriptions, new partners, and possible new uses and countries could keep demand growing—if access and pricing hold up.Read more

Oxford Biomedica is widening its manufacturing capabilities in cell and gene therapy, aiming to win more customer programs across the US and Europe while reducing reliance on any single technology. The upside is tied to growing demand and a push toward profitability, but costs, tariffs, and customer program setbacks could quickly derail momentum.Read more

Genus could unlock a new line of business if regulators sign off on its gene-editing program, adding a fresh way to grow beyond its core animal breeding work. But the story depends on how quickly China’s markets recover and whether approvals arrive on time, so the upside comes with real execution risk.Read more

Hikma is building more drug-making capacity across the US, Europe, and the Middle East while pushing into harder-to-make generic medicines and specialty injectables, aiming to meet growing demand for lower-cost treatments. But tougher competition, currency swings, and shifting rules around drug approvals could squeeze profits even if sales keep rising.Read more